Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
| NCT ID | NCT05428007 |
| Title | Interleukin-6 Receptor Inhibitor Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Patients With Unresectable Stage III or Stage IV Melanoma |
| Recruitment | Recruiting |
| Gender | both |
| Phase | Phase II |
| Variant Requirements | No |
| Sponsors | NYU Langone Health |
| Indications | |
| Therapies | |
| Age Groups: | adult | senior |
| Covered Countries | USA |
| Facility | Status | City | State | Zip | Country | Details |
|---|---|---|---|---|---|---|
| The Angeles Clinic at Cedars Sinai | RECRUITING | Los Angeles | California | 90025 | United States | Details |
| Massachusetts General Hospital | RECRUITING | Boston | Massachusetts | 02114 | United States | Details |
| Dana Farber Cancer Institute | RECRUITING | Boston | Massachusetts | 02215 | United States | Details |
| NYU Langone Health | RECRUITING | New York | New York | 10016 | United States | Details |